What changed from existing technology?
This study looked at 1,500 FDA-approved drugs to find ones that could be used again as treatments for type 2 diabetes, focusing on both how well they work and their safety.
This study is the first to combine molecular docking with comprehensive safety assessment for drug repurposing in T2DM, addressing a gap in previous computational approaches that focused only on binding affinity.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
assessment identify repurposable DPP-4 inhibitors from FDA approved drugs. Type 2 diabetes mellitus (T2DM) remains a major global health challenge, and a
Title ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
- 장기·실사용 검증 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This approach could help identify existing drugs that may be repurposed for T2DM treatment with a known safety profile, potentially reducing development time and costs.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.